# Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)

> **NCT00982150** · PHASE2 · TERMINATED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 446 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Talampanel

## Key facts

- **NCT ID:** NCT00982150
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 446 (ACTUAL)
- **Why stopped:** Core study unsuccessful
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00982150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00982150, "Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00982150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*